Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)

Inclusion Criteria: * Written informed consent and any locally-required authorization (e.g., Health Information Portability and Accountability Act \[HIPAA\] in the United States of America \[USA\], European Union \[EU\] Data Privacy Directive in the EU) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations * Histology showing high-grade epithelial non-mucinous ovarian, primary peritoneal, or fallopian tube cancer * No prior treatment for primary advanced (stage III or IV) epithelial ovarian, primary peritoneal, or fallopian tube carcinoma such as irradiation, chemotherapy, hormonal therapy, immunotherapy, investigational therapy, surgery, and/or other concurrent agents or therapies * A disposition to neoadjuvant chemotherapy with planned interval tumor reductive surgery after 3 complete cycles of treatment * Planned chemotherapy with combination carboplatin and paclitaxel given intravenously * Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 * Measurable disease is defined at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded); each target lesion must be \> 20 mm when measured by conventional techniques, including palpation, plain x-ray, computed tomography (CT), and magnetic resonance imaging (MRI), or \> 10 mm when measured by spiral CT * Patients with non-measurable but evaluable solid tumors may be deeme…